ArticleFrontiers in immunology2017
Role of Anti-Osteopontin Antibodies in Multiple Sclerosis and Experimental Autoimmune Encephalomyelitis.
Article in Frontiers in immunology, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 23 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
23 citing papers in PubMed, 40 citations in OpenAlex.
- Targeting astrocytic CLC2(CLCN2) restores myelin regeneration through inhibition of SPP1/CD44 signaling pathway in leukoencephalopathy.Molecular psychiatry · 2026Article
- Elevated osteopontin reflects systemic inflammation in experimental autoimmune encephalomyelitis.Anatomy & cell biology · 2025Article
- Osteopontin: A Versatile Biomarker-Insights and Innovations from Three Decades of Research.Biomedicines · 2024Article
- Histopathological evaluation of the lungs in experimental autoimmune encephalomyelitis.Journal of veterinary science · 2024Article
- Beyond the Biomarker: Unveiling the Multifaceted Role of Osteopontin in Both Physiological and Pathological Processes.Biomedicines · 2024Article
- Characterizing microglial gene expression in a model of secondary progressive multiple sclerosis.Glia · 2023Article
- Osteopontin Is Associated with Multiple Sclerosis Relapses.Biomedicines · 2023Article
- Associations of serum keratin 1 with thyroid function and immunity in Graves' disease.PloS one · 2023Article
- The Translatability of Multiple Sclerosis Animal Models for Biomarkers Discovery and Their Clinical Use.International journal of molecular sciences · 2022Review
- Single-cell and spatial RNA sequencing identify perturbators of microglial functions with aging.Nature aging · 2022Article
- The Role of Osteopontin in Microglia Biology: Current Concepts and Future Perspectives.Biomedicines · 2022Review
- The Role of Osteopontin in Tumor Progression Through Tumor-Associated Macrophages.Frontiers in oncology · 2022Review
- White matter injury but not germinal matrix hemorrhage induces elevated osteopontin expression in human preterm brains.Acta neuropathologica communications · 2021Article
- Circulating Osteopontin Levels and Outcomes in Patients Hospitalized for COVID-19.Journal of clinical medicine · 2021Article
- TheNeural regeneration research · 2021Review
- High levels of circulating osteopontin in inflammatory lung disease regardless of Sars-CoV-2 infection.EMBO molecular medicine · 2021Article
- Pathway-Focused Profiling of Oligodendrocytes Over-Expressing miR-125a-3p Reveals Alteration of Wnt and Cell-to-Cell Signaling.Cellular and molecular neurobiology · 2021Article
- Targeting Nuclear Factor-Kappa B Signaling Pathway by Curcumin: Implications for the Treatment of Multiple Sclerosis.Advances in experimental medicine and biology · 2021Review
- Osteopontin as a candidate of therapeutic application for the acute brain injury.Journal of cellular and molecular medicine · 2020Review
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
19 authors at 8 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Osteopontin (OPN) is highly expressed in demyelinating lesions in multiple sclerosis (MS) and experimental autoimmune encephalomyelitis (EAE). OPN is cleaved by thrombin into N- (OPN-N) and C-terminal (OPN-C) fragments with different ligands and functions. In EAE, administering recombinant OPN induces relapses, whereas treatment with anti-OPN antibodies ameliorates the disease. Anti-OPN autoantibodies (autoAbs) are spontaneously produced during EAE but have never been detected in MS. The aim of the study was to evaluate anti-OPN autoAbs in the serum of MS patients, correlate them with disease course, and recapitulate the human findings in EAE. We performed ELISA in the serum of 122 patients collected cross-sectionally, and 50 patients with relapsing-remitting (RR) disease collected at diagnosis and followed longitudinally for 10 years. In the cross-sectional patients, the autoAb levels were higher in the RR patients than in the primary- and secondary-progressive MS and healthy control groups, and they were highest in the initial stages of the disease. In the longitudinal group, the levels at diagnosis directly correlated with the number of relapses during the following 10 years. Moreover, in patients with active disease, who underwent disease-modifying treatments, autoAbs were higher than in untreated patients and were associated with low MS severity score. The autoAb displayed neutralizing activity and mainly recognized OPN-C rather than OPN-N. To confirm the clinical effect of these autoAbs
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.